Patients with metastatic colorectal cancer who were treated with a biweekly dose of trifluridine-tipiracil (TAS-102) saw similar treatment effectiveness and reduced toxicity compared with treatment using standard dosing schedules, according to a recent study in The Oncologist that was co-authored by a Fox Chase Cancer Center physician.